

**CURRICULUM VITAE**  
**Luca Pani, MD**

1. *Date: July 25<sup>th</sup>, 2022*

**I. Personal**

2. *Name: Luca Pani*

3. *Home Phone: 1 (XXX) XXX-XXX / mobile US 1 (XXX) EU 39*

4. *Office Phone: 1 (305) 243-3487*

5. *Home Address: XXXXXX*

6. *Current Academic Rank: Full Professor both in US and ITALY*

6A. *Current Track of US Appointment: Clinical Educator Track*

7. *Primary Department: Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, USA*

8. *Joint Appointment: Full Professor and Chair of Pharmacology and Clinical Pharmacology, University of Modena and Reggio Emilia, School of Medicine, Modena, Italy (tenured)*

9. *Citizenship: American (primary) and Italian*

10. *Visa Type: N/A*

**II. Higher Education**

11. *Institutional:*

*1990-1991 the University of Illinois at Chicago, USA – Post-Doctoral Fellowship in Molecular Biology*

*1985-1989 University of Naples, Italy – Specialty in Psychiatry*

*1979-1985 University of Cagliari, Italy – Medical Degree*

12. *Non-Institutional:*

13. *Certification and Licensure:*

*Specialty Certification Psychiatry, Naples - Italy, July 1989*

*Board Certification to practice Medicine, Cagliari - Italy, December 1985*

**III. Experience**

*Academic*

*2018-present Full Professor and Chair of Pharmacology and Clinical Pharmacology (tenured), Department of Biomedical, Metabolic and Neural Sciences, the University of Modena and Reggio Emilia, Modena, Italy*

2018-present Director Master I Level on “From Prevention to Clinical Skills of Alcohol Abuse related issues,” University of Modena and Reggio Emilia, Modena, Italy  
2017-present Full Professor of Clinical Psychiatry, Educator Track, Department of Psychiatry and Behavioral Sciences, University of Miami – M. Miller School of Medicine, Miami, USA  
2011-2017 Voluntary Professor, Department of Psychiatry and Behavioral Sciences, University of Miami – M. Miller School of Medicine  
2007-2017 Appointed Teaching Professor, Courses on Psychopharmacology, Residency in Psychiatry, School of Medicine, University of Cagliari, Italy  
2001-2018 Director of Research, Italian National Research Council (CNR) – Rome, Italy  
1999-2001 First Researcher, Italian National Research Council (CNR) – Rome, Italy  
1995-1999 Researcher, Italian National Research Council (CNR) – Rome, Italy  
1992-1994 Assistant Professor in Molecular Biology and Pharmacology, Georgetown University, Washington DC, USA

15. Hospital Appointments:

1990-2010 Chief Psychiatrist, Centro San Michele, Cagliari Italy, Private Institution  
1988-1989 Medical Assistant (tenured). Public Psychiatric Hospital “Villa Clara”. Cagliari, Italy  
1985-1988 Resident in Psychiatry, Centro Lucio Bini, Rome, Italy, Private Institution

16. Non-Academic:

2022- current Chief Innovation and Regulatory Officer, Nurosene Health Inc., CANADA  
2021-current Chief Clinical Operations and Strategic Development, Relmada Therapeutics, USA  
2021-current VP for Regulatory Strategy and Market Access Innovation, WCG, Clinical Endpoint Solutions – Princeton, USA  
2017- current Chief Scientific Officer – EDRA-LSWR Publishing Company, Milan, Italy  
2018-2021 VP for Regulatory Strategy and Market Access Innovation, VeraSci, Durham, NC, USA  
2017-2018 Executive Director for Global Medical Innovation, NeuroCogTrial (now VeraSci), Durham, NC, USA  
2017-2021 Chief Scientific Officer – Inpeco Automation Healthcare Company, Lugano, Switzerland  
2011-2016 Director General, Italian Medicines Agency (AIFA), Rome, Italy  
2013-2016 Chair of the European Union Management Board Telematic Committee (EUMBTC) of the European Medicines Agency (EMA), London UK  
2016-2017 Chair of the EMA EU Network Pharmacovigilance Oversight Group, London UK  
2011-2016 Member Management Board of the European Medicines Agency (EMA), London UK  
2010- 2017 Italian Permanent Member, Committee for Human Medicine Products (CHMP), of the European Medicines Agency (EMA), London UK  
2010-2017 Member of the Scientific Advice Working Party (SAWP), of the European Medicines Agency (EMA), London UK  
2010-2017 Member and then Participant of the Working Group on Central Nervous System (WG-CNS), of the European Medicines Agency (EMA), London UK  
2015-2016 Member of the Management Group Heads of Medicines Agencies (HMA)  
2013-2016 Chair of the European Risk Management Strategy Facilitation Group (ERMS-FG) of the European Medicines Agency (EMA), London UK  
2009-2011 Member, Committee for Clinical Neurosciences, Italian Medicines Agency (AIFA)  
2009-2011 Head of Research of the National Research Council’s Institute of Translational pharmacology (CNR – ITP), Pula-Cagliari, Italy  
2008-2010 3PS Media Ltd Consultant

2008-2011 Founder and Permanent Member of the Scientific Board of Fase 1, the first Government based (Regione Autonoma della Sardegna) Contract Research Organization dedicated to Phase I studies

2006-2010 Head Section of Neuropharmacology Pula-Cagliari, Institute of Biomedical Technologies, Milan Italian National Research Council (CNR)

2001-2018 Director of Research, CNR. Cagliari-Rome

2002-2010 President, Pharmaness Neuroscienze (Board of Directors member).

2004-2009 President, Proteios Srl

2005-2008 President ProKemia Consorzio

1999-2002 CEO, Pharmaness Neuroscienze Consortium

17. Military:

1986-1988, Lieutenant Medical Officer of the Italian Navy. Commander South Sardinia General Medicine Headquarters, Cagliari, Italy

#### IV. Peer Reviewed Publications PubMed Luca Pani's Bibliography here:

<https://pubmed.ncbi.nlm.nih.gov/?term=pani+l.&sort=date>

1. Guerzoni S, Baraldi C, Pani L.  
*The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine. Neurol Sci. 2022 Jun 10. doi: 10.1007/s10072-022-06195-5.*
2. Persico AM, Ricciardello A, Alessandrini S, Viola L, Bergonzini P, Iughetti L, Pani L.  
*Depression and Catatonia Associated With Lansoprazole in an Adolescent With Phelan-McDermid Syndrome: A Case Report. J Clin Psychopharmacol. 2022 May 13. doi: 10.1097/JCP.0000000000001555. Online ahead of print. PMID: 35551397*
3. Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, Cevoli S, Pani L.  
*Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci. 2022 Jan 11; doi: 10.1007/s10072-022-05870-x. [Epub ahead of print] PubMed PMID: 35015202.*
4. Cammarata SM, Capone G, Lombardi N, Pani L, Mugelli A. *Systematic Data Monitoring and Analysis of Cardiovascular Off-label Prescriptions in Pediatrics: Focus on Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Beta Blockers. High Blood Press Cardiovasc Prev. 2022 Jan 8;. doi: 10.1007/s40292-021-00499-x. [Epub ahead of print] PubMed PMID: 34997917.*
5. Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi CE, Manfredi PL. *REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. Am J Psychiatry. 2021 Dec 22;:appiajp202121020197. doi: 10.1176/appi.ajp.2021.21020197. [Epub ahead of print] PubMed PMID: 34933568.*

6. Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A, Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx BWJH, Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen-Ducuing F, Fletcher C, Haberkamp M, Laughren T, M<sup>n</sup>tyl<sup>l</sup> FL, Schruers K, Thomson A, Arteaga-Henr<sup>l</sup>quez G, Benedetti F, Cash-Gibson L, Chae WR, De Smedt H, Gold SM, Hoogendijk WJG, Mondrag<sup>n</sup> VJ, Maron E, Martynowicz J, Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM. *A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.* *Mol Psychiatry.* 2021 Dec 15;. doi: 10.1038/s41380-021-01381-x. [Epub ahead of print] Review. PubMed PMID: 34907394.
7. Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S. *Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.* *Neurol Sci.* 2021 Oct;42(10):4193-4202. doi: 10.1007/s10072-021-05105-5. Epub 2021 Feb 5. PubMed PMID: 33547541.
8. Baraldi C, Lo Castro F, Negro A, Ferrari A, Cainazzo MM, Pani L, Guerzoni S. *Oral cannabinoid preparations for the treatment of chronic migraine: a retrospective study.* *Pain Med.* 2021 Aug 4:p<sup>nab</sup>245. doi: 10.1093/pm/p<sup>nab</sup>245. Online ahead of print. PMID: 34347088
9. Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. *Predictors of response to erenumab after 12 months of treatment.* *Brain Behav.* 2021 Jul 16. doi: 10.1002/brb3.2260. Online ahead of print. PMID: 34268907
10. Blom JMC, Colliva C, Benatti C, Tascetta F, Pani L. *Digital Phenotyping and Dynamic Monitoring of Adolescents Treated for Cancer to Guide Intervention: Embracing a New Era.* *Front Oncol.* 2021 Jun 28;11:673581. doi: 10.3389/fonc.2021.673581. eCollection 2021.
11. Pani L, Becker K. *New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing.* *Clin Drug Investig.* 2021 Jun;41(6):529-537. doi: 10.1007/s40261-021-01041-6. Epub 2021 May 20. PMID: 34014509 Review.
12. Skeen MB, Pani L. *Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues.* *J Clin Neurophysiol.* 2021 May 1;38(3):181-185. doi:10.1097/WNP.0000000000000732. PMID: 33958568
13. Baraldi C, Ornello R, Favoni V, Sacco S, Caponnetto V, Pierangeli G, Pani L, Cevoli S, Guerzoni S. *Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic.* *Front Neurol.* 2021 Apr 15;12:647995. doi: 10.3389/fneur.2021.647995. eCollection 2021. PMID: 33935945

14. Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni  
*Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. S.Neurol Sci. 2021 Feb 5. doi: 10.1007/s10072-021-05105-5. Online ahead of print.PMID: 33547541*
15. Russo PL, Pani L, Staniscia T, Romano F, Marzioni M.,  
*Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries. Eur Rev Med Pharmacol Sci. 2020 May;24(10):5758-5768. doi: 10.26355/eurrev\_202005\_21368.*
16. Trifirò GL, Crisafulli S, Andò G, Racagni G., Filippo Drago, and the Italian Society of Pharmacology Collaborators: Berrino L, Re M, Bernardini R, Chiamulera C, D'Avolio A, Pani L, Clementi E, Capuano A, Scaglione F, Danesi R, Cirino G, Mugelli A, Bonanno GB, Brunello N, de Luca A, Hrelia P, Pistis M, Ghelardini C, Tagliatalata M.,  
*Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers Be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Drug Saf, 2020 Apr 17. doi: 10.1007/s40264-020-00935-2. Online ahead of print.*
17. Pammolli F, Righetto L, Abrignani S, Pani L, Pelicci PG, Rabosio E.  
*The endless frontier? The recent increase of R&D productivity in pharmaceuticals. J Transl Med. 2020 Apr 9;18(1):162. doi: 10.1186/s12967-020-02313-z.*
18. Baraldi C, Gherpelli C, Alicandri Ciufelli M, Monzani D, Pini LA, Pani L, Guerzoni S.  
*A case-control study of visually evoked postural responses in childhood with primary headaches. Neurol Sci. 2020 Feb;41(2):305-311. doi: 10.1007/s10072-019-04072-2.*
19. Pani L, Keefe RSE.  
*Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. Schizophr Res Cogn. 2019 Jun 14;18:100155*
20. Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D.  
*Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol. 2019 Jul 14;269881119857204. doi: 10.1177/0269881119857204.*
21. Keefe RSE, Pani L.,  
*Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Nov;3(11):900-902. doi: 10.1016/j.bpsc.2018.09.002.*
22. Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

- Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection. 2018 May 28. doi: 10.1007/s15010-018-1157-x.*
23. Santini A, Cammarata SM, Capone G, Ianaro A, Tenore GC, Pani L, Novellino E. *Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018 Apr;84(4):659-672. doi: 10.1111/bcp.13496. Epub 2018 Feb 14. Review. PMID: 29433155*
24. Lepelaars LRA, Renda F, Pani L, Pimpinella G, Leufkens HGM, Trifirò G, Tafuri G, Mantel-Teeuwisse AK, Trotta F. *Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. Br J Clin Pharmacol. 2018 Apr;84(4):738-763. doi: 10.1111/bcp.13454. Epub 2018 Jan 18*
25. Martini S, Donato MF, Mazzarelli C, Rendina M, Visco-Comandini U, Filì D, Gianstefani A, Fagioli S, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Carrai P, Caraceni P; ITACOPS study group. *The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. Liver Int. 2017 Sep 16. doi: 10.1111/liv.13588. [Epub ahead of print] PubMed PMID: 28921807.*
26. Gozzo L, Navarria A, Benfatto G, Longo L, Mansueto S, Sottosanti L, Pani L, Salomone S, Drago F. *Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network. Clin Drug Investig. 2017 Nov;37(11):1067-1081. doi: 10.1007/s40261-017-0566-4. PubMed PMID: 28856572.*
27. Carrai P, Morelli C, Cordone G, Romano A, Tamé M, Lionetti R, Pietrosi G, Lenci I, Piai G, Russo FP, Coppola C, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Martini S, Toniutto P; ITACOPS study group. *The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transpl Int. 2017 Aug 11. doi: 10.1111/tri.13018. [Epub ahead of print] PubMed PMID: 28799277.*
28. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. *Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. PubMed PMID: 28497758.*
29. Marengoni A, Onder G, Degli Esposti L, Russo P, Sangiorgi D, Buda S, Fini M, Marchionni N, Bonassi S, Mammarella F, Marrocco W, Pozzi G, Palmer K, Monaco A, Pecorelli S, Pani L; Geriatrics Steering Committee of the Italian Medicines Agency on behalf of the OsMed Health-DB Network. *Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons: Evidence From the Italian Nationwide OsMed Health-DB Database. J Clin Psychiatry. 2016 Dec;77(12):1712-1718. doi:10.4088/JCP.15m10503. PubMed PMID: 28086009.*

30. Longo A, Casuccio A, Pani L, Avitabile T, Cillino S, Uva MG, Bonfiglio V, Russo A, Parisi G, Cennamo G, Furino C, Parravano M, Xoxi E, Reibaldi M. Association of neovascular age-related macular degeneration with month and season of birth in Italy. *Aging (Albany NY)*. 2016 Dec 19;9(1):133-141. doi: 10.18632/aging.101137. PubMed PMID: 27997361; PubMed Central PMCID: PMC5310660.
31. Renda F, Marotta E, Landoni G, Belletti A, Cuconato V, Pani L. Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases. *Int J Cardiol*. 2016 Dec 1;224:406-411. doi: 10.1016/j.ijcard.2016.09.066. Epub 2016 Sep PubMed PMID: 27684599.
32. Faulkner SD, Lee M, Qin D, Morrell L, Xoxi E, Sammarco A, Cammarata S, Russo P, Pani L, Barker R. Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. *Clin Pharmacol Ther*. 2016 Dec;100(6):730-742. doi: 10.1002/cpt.508. Epub 2016 Oct 22. Review. PubMed PMID: 27626221.
33. Menditto E, Bolufer De Gea A, Cahir C, Marengoni A, Riegler S, Fico G, Costa E, Monaco A, Pecorelli S, Pani L, Prados-Torres A. Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification. *Clinicoecon Outcomes Res*. 2016 Jun 13;8:253-65. doi: 10.2147/CEOR.S97548. eCollection 2016. PubMed PMID: 27358570; PubMed Central PMCID: PMC4912318.
34. Pani L, Montilla S, Németh G, Russo P, Viceconte G, Vogler S. Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). *Pharmacol Res*. 2016 Sep;111:247-250. doi: 10.1016/j.phrs.2016.05.022. Epub 2016 Jun 9. PubMed PMID: 27293051.
35. Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C, Banaschewski T, Baron-Cohen S, Broich K, Bölte S, Bourgeron T, Charman T, Collier D, de Andres-Trelles F, Durston S, Ecker C, Elferink A, Haberkamp M, Hemmings R, Johnson MH, Jones EJ, Khwaja OS, Lenton S, Mason L, Mantua V, Meyer-Lindenberg A, Lombardo MV, O'Dwyer L, Okamoto K, Pandina GJ, Pani L, Persico AM, Simonoff E, Tauscher-Wisniewski S, Llinares-Garcia J, Vamvakas S, Williams S, Buitelaar JK, Murphy DG. Identification and validation of biomarkers for autism spectrum disorders. *Nat Rev Drug Discov*. 2016 Jan;15(1):70-3. doi: 10.1038/nrd.2015.7. PubMed PMID: 26718285.
36. Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. *Int J Technol Assess Health Care*. 2015 Jan;31(4):210-3. doi: 10.1017/S0266462315000446. PubMed PMID: 26646859.
37. Renda F, Landoni G, Trotta F, Piras D, Finco G, Felicetti P, Pimpinella G, Pani L. Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database. *Int J Cardiol*. 2016 Jan 15;203:217-20. doi: 10.1016/j.ijcard.2015.10.003. Epub 2015 Oct 22. Review. PubMed PMID: 26512841.
38. Onder G, Marengoni A, Russo P, Degli Esposti L, Fini M, Monaco A, Bonassi S, Palmer K, Marrocco W, Pozzi G, Sangiorgi D, Buda S, Marchionni N, Mammarella F, Bernabei R, Pani

- L, Pecorelli S; Geriatrics Working Group of the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA); Medicines Utilization Monitoring Center Health Database Network. Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. J Am Med Dir Assoc. 2016 Feb;17(2):168-72. doi: 10.1016/j.jamda.2015.08.009. PubMed PMID: 26441359.*
39. Renda F, Landoni G, Bertini Malgarini R, Assisi A, Azzolini ML, Mucchetti M, Pimpinella G, Pani L. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance. *Drug Saf.* 2015 Dec;38(12):1211-8. doi: 10.1007/s40264-015-0343-3. PubMed PMID: 26370105.
  40. Guarienti M, Giacomuzzi E, Gianoncelli A, Sigala S, Spano P, Pecorelli S, Pani L, Memo M. Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. *Pharmacol Res.* 2015 Dec;102:12-21. doi: 10.1016/j.phrs.2015.09.004. Epub 2015 Sep 8. PubMed PMID: 26361727.
  41. Gianoncelli A, Bonini SA, Bertuzzi M, Guarienti M, Vezzoli S, Kumar R, Delbarba A, Mastinu A, Sigala S, Spano P, Pani L, Pecorelli S, Memo M. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. *BioDrugs.* 2015 Aug;29(4):285-300. doi: 10.1007/s40259-015-0136-3. PubMed PMID: 26334631; PubMed Central PMCID: PMC4562010.
  42. Messori A, De Rosa M, Fadda V, Pani L. Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer. *J Clin Oncol.* 2015 Nov 10;33(32):3838-9. doi: 10.1200/JCO.2015.61.8991. Epub 2015 Aug 24. PubMed PMID: 26304897.
  43. Borg JJ, Tomasi P, Pani L, Aislaitner G, Pirozynski M, Leufkens H, Melchiorri D. Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective. *Sci Pharm.* 2014 May 22;82(4):847-56. doi: 10.3797/scipharm.1312-10. Print 2014 Oct-Dec. PubMed PMID: 26171329; PubMed Central PMCID: PMC4475802.
  44. Fadini GP, Avogaro A, Degli Esposti L, Russo P, Saragoni S, Buda S, Rosano G, Pecorelli S, Pani L; OsMed Health-DB Network. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. *Eur Heart J.* 2015 Sep 21;36(36):2454-62. doi: 10.1093/eurheartj/ehv301. Epub 2015 Jun 25. PubMed PMID: 26112890.
  45. Borg JJ, Laslop A, Pani L, Maciulaitis R, Melchiorri D. Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ. *Sci Pharm.* 2014 Mar 24;82(3):541-54. doi: 10.3797/scipharm.1402-14. Print 2014 Jul-Sep. PubMed PMID: 25853067; PubMed Central PMCID: PMC4318218.
  46. Haas M, Mantua V, Haberkamp M, Pani L, Isaac M, Butlen-Ducuing F, Vamvakas S, Broich K. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. *Nat Rev Drug Discov.* 2015 Apr;14(4):221-2. doi: 10.1038/nrd4585. PubMed PMID: 25829266.



47. Pelliccia F, Coats AJ, Pani L, Gaudio C, Rosano G. Transparency in medical research: Time for a paradigm shift. *Int J Cardiol.* 2015;186:259-60. doi:10.1016/j.ijcard.2015.03.219. Epub 2015 Mar 18. PubMed PMID: 25828129.
48. Ehmman F, Papaluca M, Di Giuseppe F, Pani L, Eskova A, Manolis E, Herold R. Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union. *Expert Opin Pharmacother.* 2015 Apr;16(6):903-11. doi: 10.1517/14656566.2015.1025050. Epub 2015 Mar 14. Review. PubMed PMID: 25773468.
49. Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, Merlini G, Schaefer F, Simoens S, Pani L, Garattini S, Remuzzi G. Rare diseases and effective treatments: are we delivering? *Lancet.* 2015 Feb 28;385(9970):750-2. doi: 10.1016/S0140-6736(15)60297-5. PubMed PMID: 25752159.
50. Messori A, De Rosa M, Pani L. Alternative pricing strategies for cancer drugs. *JAMA.* 2015 Feb 24;313(8):857. doi: 10.1001/jama.2014.17814. PubMed PMID: 25710668.
51. Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, Mohs R, Lalonde R, Sinha V, Wang Y, Brown D, Isaac M, Vamvakas S, Hemmings R, Pani L, Bain LJ, Corrigan B; Alzheimer's Disease Neuroimaging Initiative; Coalition Against Major Diseases. The future is now: model-based clinical trial design for Alzheimer's disease. *Clin Pharmacol Ther.* 2015 Mar;97(3):210-4. doi: 10.1002/cpt.16. Epub 2014 Dec 27. PubMed PMID: 25669145.
52. Pani L, Pecorelli S, Rosano G, Anker SD, Peracino A, Fregonese L, Prasad K, Rasi G. Steps forward in regulatory pathways for acute and chronic heart failure. *Eur J Heart Fail.* 2015 Jan;17(1):3-8. doi: 10.1002/ejhf.209. Review. PubMed PMID:25597869.
53. Savarese G, Perrone-Filardi P, D'Amore C, Vitale C, Trimarco B, Pani L, Rosano GM. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. *Int J Cardiol.* 2015 Feb 15;181:239-44. doi:10.1016/j.ijcard.2014.12.017. Epub 2014 Dec 3. PubMed PMID: 25528528.
54. Pani L, Pecorelli S, Rosano G, Anker SD, Peracino A, Fregonese L, Prasad K, Rasi G. Steps forward in regulatory pathways for acute and chronic heart failure. *ESC Heart Fail.* 2014 Dec;1(2):87-93. doi: 10.1002/ehf2.12015. Epub 2015 Jan 20. Review. PubMed PMID: 28834626.
55. Principi N, Caironi M, Venturini F, Pani L, Esposito S. Daptomycin in paediatrics: current knowledge and the need for future research. *J Antimicrob Chemother.* 2015 Mar;70(3):643-8. doi: 10.1093/jac/dku453. Epub 2014 Nov 17. Review. PubMed PMID: 25406298.
56. Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C, Melchiorri D, Pani L; AIFA Anti-diabetics Monitoring Group. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. *Nutr Metab Cardiovasc Dis.* 2014 Dec;24(12):1346-53. doi: 10.1016/j.numecd. 2014.07.014. Epub 2014 Oct 6. PubMed PMID: 25300980.

57. Juckel G, de Bartolomeis A, Gorwood P, Mosolov S, Pani L, Rossi A, Sanjuan J. Towards a framework for treatment effectiveness in schizophrenia. *Neuropsychiatr Dis Treat*. 2014 Sep 24;10:1867-78. doi: 10.2147/NDT.S61672. eCollection 2014. PubMed PMID: 25285010; PubMed Central PMCID: PMC4181746.
58. Hill DL, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephenson D. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in prodromal stages of Alzheimer's disease. *Alzheimers Dement*. 2014 Jul;10(4):421-9.e3. doi: 10.1016/j.jalz.2013.07.003. PubMed PMID: 24985687.
59. Naldi I, Taranta M, Gherardini L, Pelosi G, Viglione F, Grimaldi S, Pani L, Cinti C. Novel epigenetic target therapy for prostate cancer: a preclinical study. *PLoS One*. 2014 May 22;9(5):e98101. doi: 10.1371/journal.pone.0098101. eCollection 2014. PubMed PMID: 24851905; PubMed Central PMCID: PMC4031137.
60. Salvo I, Landoni G, Mucchetti M, Cabrini L, Pani L. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience. *Paediatr Anaesth*. 2014 Jun;24(6):625-31. doi: 10.1111/pan.12403. Epub 2014 May 3. PubMed PMID: 24796404.
61. Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, Broich K, Cummings J, Dening K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, Muscolo LA, Nicolas F, Pani L, Robinson L, Siviero P, van Dam J, Van Emelen J, Wimo A, Wortmann M, Goh L. Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. *Alzheimers Dement*. 2015 Apr;11(4):455-61. doi:10.1016/j.jalz.2014.01.007. Epub 2014 Apr 21. PubMed PMID: 24751826.
62. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. *CNS Drugs*. 2014 May;28(5):421-53. doi: 10.1007/s40263-014-0157-3. Review. PubMed PMID: 24677189; PubMed Central PMCID: PMC4022988.
63. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. *J Intern Med*. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191. Review. PubMed PMID: 24605808; PubMed Central PMCID: PMC3956752.
64. Bianco P, Cattaneo E, De Luca M, Pani L. Stamina therapies: Let the record stand. *Nature*. 2014 Feb 27;506(7489):434. doi: 10.1038/506434c. PubMed PMID:24572414.
65. Calizzani G, Vaglio S, Vetrugno V, Delbò M, Pani L, Grazzini G. Management of notifications of donors with Creutzfeldt-Jakob disease (post-donation information). *Blood Transfus*. 2014 Jan;12(1):22-7. doi: 10.2450/2013.0035-13. Epub 2013 Oct 2. Review. PubMed PMID: 24120593; PubMed Central PMCID: PMC3926723.

66. Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, Draï C, Fiedor P, Flory E, Hudson I, Leufkens HG, Müller-Berghaus J, Narayanan G, Neugebauer B, Pokrotnieks J, Robert JL, Salmonson T, Schneider CK. Regulatory evaluation of Glybera in Europe - two committees, one mission. *Nat Rev Drug Discov*. 2013 Sep;12(9):719. doi: 10.1038/nrd3835-c1. Epub 2013 Aug 19. PubMed PMID: 23954897.
67. Onder G, Bonassi S, Abbatecola AM, Folino-Gallo P, Lapi F, Marchionni N, Pani L, Pecorelli S, Sancarolo D, Scuteri A, Trifirò G, Vitale C, Zuccaro SM, Bernabei R, Fini M; Geriatrics Working Group of the Italian Medicines Agency. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). *J Gerontol A Biol Sci Med Sci*. 2014 Apr;69(4):430-7. doi: 10.1093/gerona/glt118. Epub 2013 Aug 2. PubMed PMID: 23913935.
68. Pani L, Montilla S, Pimpinella G, Bertini Malgarini R. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. *Expert Opin Biol Ther*. 2013 Oct;13(10):1343-6. doi:10.1517/14712598.2013.815722. Epub 2013 Jun 28. PubMed PMID: 23805906.
69. Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G. Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. *Eur Rev Med Pharmacol Sci*. 2013 Feb;17 Suppl 1:45-9. Review. PubMed PMID: 23436666.
70. Chiurciu S, Calo Carducci FI, Rocchi F, Simonetti A, Bonatti G, Salmaso S, Melchiorri D, Pani L, Rossi P. Is HCMV vaccine an unmet need? The state of art of vaccine development. *Int J Immunopathol Pharmacol*. 2013 Jan-Mar;26(1):15-26. Review. PubMed PMID: 23527705.
71. Cherubini A, Nisticò G, Rozzini R, Liperoti R, Di Bari M, Zampi E, Ferrannini L, Aguglia E, Pani L, Bernabei R, Marchionni N, Trabucchi M. Subthreshold depression in older subjects: an unmet therapeutic need. *J Nutr Health Aging*. 2012 Oct;16(10):909-13. doi: 10.1007/s12603-012-0373-9. PubMed PMID: 23208031.
72. Tafuri G, Trotta F, Leufkens HG, Pani L. Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency. *Br J Clin Pharmacol*. 2013 Apr;75(4):1149-51. doi: 10.1111/j.1365-2125.2012.04424.x. PubMed PMID: 22891872; PubMed Central PMCID: PMC3612734.
73. Perugi G, Fornaro M, Maremmanni I, Canonico PL, Carbonatto P, Mencacci C, Muscettola G, Pani L, Torta R, Vampini C, Parazzini F, Dumitriu A, Angst J; Come To Me Study Group. Discriminative hypomania checklist-32 factors in unipolar and bipolar major depressive patients. *Psychopathology*. 2012;45(6):390-8. doi:10.1159/000338047. Epub 2012 Aug 7. PubMed PMID: 22890230.
74. Isaac M, Pani L, Gispén-de Wied C, Koch A. European licensing of maintenance treatment in schizophrenia. *Lancet*. 2012 Aug 11;380(9841):562-3. doi: 10.1016/S0140-6736(12)61327-0. PubMed PMID: 22883503.

75. Murineddu G, Asproni B, Ruiu S, Deligia F, Falzoi M, Pau A, Thomas BF, Zhang Y, Pinna GA, Pani L, Lazzari P. Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. *Open Med Chem J.* 2012;6:1-14. doi: 10.2174/1874104501206010001. Epub 2012 May 17. PubMed PMID: 22876271; PubMed Central PMCID: PMC3406267.
76. Butlen-Ducuing F, Haas M, Pani L, van Zwieten-Boot B, Broich K. DSM-5 and clinical trials in psychiatry: challenges to come? *Nat Rev Drug Discov.* 2012 Aug;11(8):583-4. doi: 10.1038/nrd3811. PubMed PMID: 22850770.
77. Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P. NESS038C6, a novel selective CBI antagonist agent with anti-obesity activity and improved molecular profile. *Behav Brain Res.* 2012 Oct 1;234(2):192-204. doi: 10.1016/j.bbr.2012.06.033. Epub 2012 Jul 4. PubMed PMID: 22771813.
78. Gispen-de Wied C, Stoyanova V, Yu Y, Isaac M, Pani L, de Andres-Trelles F. The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma. *Eur Neuropsychopharmacol.* 2012 Nov;22(11):804-11. doi:10.1016/j.euroneuro.2012.03.007. Epub 2012 Jun 15. Review. PubMed PMID: 22704716.
79. Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. *Eur Neuropsychopharmacol.* 2011 Nov;21(11):781-8. doi: 10.1016/j.euroneuro.2011.08.003. Epub 2011 Sep 7. PubMed PMID: 21903360.
80. Rihmer Z, Gonda X, Döme P, Erdős P, Ormos M, Pani L. Novel approaches to drug-placebo difference calculation: evidence from short-term antidepressant drug-trials. *Hum Psychopharmacol.* 2011 Jun-Jul;26(4-5):307-12. doi:10.1002/hup.1206. Epub 2011 Jul 14. PubMed PMID: 21755539.
81. Maremmani I, Perugi G, Rovai L, Maremmani AG, Pacini M, Canonico PL, Carbonato P, Mencacci C, Muscettola G, Pani L, Torta R, Vampini C, Akiskal HS. Are "social drugs" (tobacco, coffee and chocolate) related to the bipolar spectrum? *J Affect Disord.* 2011 Sep;133(1-2):227-33. doi: 10.1016/j.jad.2011.04.019. Epub 2011 May 24. PubMed PMID: 21605911.
82. Fornaro M, Maremmani I, Canonico PL, Carbonatto P, Mencacci C, Muscettola G, Pani L, Torta R, Vampini C, Parazzini F, Dumitriu A, Perugi G. Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients. *Neuropsychiatr Dis Treat.* 2011;7:217-21. doi: 10.2147/NDT.S17949. Epub 2011 Apr 21. PubMed PMID: 21573083; PubMed Central PMCID: PMC3090285.
83. Perugi G, Canonico PL, Carbonato P, Mencacci C, Muscettola G, Pani L, Torta R, Vampini C, Fornaro M, Parazzini F, Dumitriu A; Come To Me Study Group. Unexplained somatic symptoms during major depression: prevalence and clinical impact in a national sample of

- Italian psychiatric outpatients. Psychopathology. 2011;44(2):116-24. doi: 10.1159/000319848. Epub 2011 Jan 12. PubMed PMID: 21228616.*
84. Lazzari P, Sanna A, Mastinu A, Cabasino S, Manca I, Pani L. *Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behav Brain Res. 2011 Mar 1;217(2):432-8. doi: 10.1016/j.bbr.2010.11.022. Epub 2010 Nov 11. PubMed PMID: 21074566.*
85. Pisu C, Pira L, Pani L. *Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent. Behav Pharmacol. 2010 Oct;21(7):649-53. doi: 10.1097/FBP.0b013e32833e7eab. PubMed PMID: 20802307.*
86. Lazzari P, Fadda P, Marchese G, Casu GL, Pani L. *Antinociceptive activity of Delta9 tetrahydrocannabinol non-ionic microemulsions. Int J Pharm. 2010 Jun 30;393(1-2):238-43. doi: 10.1016/j.ijpharm.2010.04.010. Epub 2010 Apr 23. PubMed PMID: 20399844.*
87. Falzoi M, Mossa A, Congeddu E, Saba L, Pani L. *Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. Pharmacogenomics. 2010 Apr;11(4):559-71. doi: 10.2217/pgs.09.172. PubMed PMID: 20350138.*
88. Pani L. *The need for individualised antipsychotic drug therapy in patients with schizophrenia. Eur Rev Med Pharmacol Sci. 2009 Nov-Dec;13(6):453-9. Review. PubMed PMID: 20085126.*
89. Sanna D, Sanna A, Mara L, Pilichi S, Mastinu A, Chessa F, Pani L, Dattena M. *Oct4 expression in in-vitro-produced sheep blastocysts and embryonic-stem-like cells. Cell Biol Int. 2009 Dec 16;34(1):53-60. doi: 10.1042/CBI20090008. PubMed PMID: 19947952.*
90. Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, Rossi FS, Lazzari P, Pani L, de Novellis V, Malcangio M, Maione S. *1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis. 2010 Jan;37(1):177-85. doi: 10.1016/j.nbd.2009.09.021. Epub 2009 Oct 3. PubMed PMID: 19804829.*
91. Marchese G, Casu G, Casti P, Spada GP, Pani L. *Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats. Eur J Pharmacol. 2009 Oct 12;620(1-3):36-41. doi: 10.1016/j.ejphar.2009.07.024. Epub 2009 Aug 5. PubMed PMID: 19664616.*
92. Marchese G, Pittau B, Casu G, Peddio G, Spada GP, Pira M, Deriu A, Portesani F, Pisu C, Lazzari P, Pani L. *A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. Eur Psychiatry. 2010 Mar;25(2):92-100. doi: 10.1016/j.eurpsy.2009.05.008. Epub 2009 Jul 28. PubMed PMID: 19640686.*
93. Olimpieri F, Tambaro S, Fustero S, Lazzari P, Sanchez-Roselló M, Pani L, Volonterio A, Zanda M. *Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual*

- ACE/NEP inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4715-9. doi: 10.1016/j.bmcl.2009.06.064. Epub 2009 Jun 21. PubMed PMID: 19596577.*
94. Sinisi R, Ghilardi A, Ruiu S, Lazzari P, Malpezzi L, Sani M, Pani L, Zanda M. *Synthesis and in vitro Evaluation of Trifluoroethylamine Analogues of Enkephalins. ChemMedChem. 2009 Sep;4(9):1416-20. doi: 10.1002/cmde.200900158. PubMed PMID: 19533725.*
95. Pani L, Marchese G. *Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv. 2009 Mar;6(3):319-31. doi: 10.1517/17425240902780158. Review. PubMed PMID: 19317589.*
96. Marchese G, Sanna A, Casu G, Casti P, Spada GP, Ruiu S, Pani L. *Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration. Eur J Pharmacol. 2008 Nov 19;598(1-3):16-20. doi: 10.1016/j.ejphar.2008.08.020. Epub 2008 Aug 30. PubMed PMID: 18789920.*
97. Pani L, Villagrán JM, Kontaxakis VP, Alptekin K. *Practical issues with amisulpride in the management of patients with schizophrenia. Clin Drug Investig. 2008;28(8):465-77. Review. PubMed PMID: 18598092.*
98. Mongeau R, Casu MA, Pani L, Pillolla G, Lianas L, Giachetti A. *Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology content over the Internet. Comput Methods Programs Biomed. 2008 May;90(2):124-36. doi: 10.1016/j.cmpb.2007.12.007. Epub 2008 Feb 11. PubMed PMID: 18262677.*
99. Mongeau R, Marcello S, Andersen JS, Pani L. *Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice. Behav Brain Res. 2007 Nov 2;183(2):147-55. Epub 2007 Jun 12. PubMed PMID: 17629580.*
100. Pani L, Pira L, Marchese G. *Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry. 2007 Jul;22(5):267-75. Epub 2007 Apr 6. Review. PubMed PMID: 17419008.*
101. Loriga G, Ruiu S, Manca I, Murineddu G, Dessi C, Pani L, Pinna GA. *3-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-6-substituted-3,6-diazabicyclo[3.1.1]heptanes as novel potent dopamine uptake inhibitors. Bioorg Med Chem. 2007 Jun 1;15(11):3748-55. Epub 2007 Mar 16. PubMed PMID: 17399987.*
102. Casu MA, Sanna A, Spada GP, Falzoi M, Mongeau R, Pani L. *Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens. Brain Res. 2007 Apr 13;1141:15-24. Epub 2007 Jan 8. PubMed PMID:17270156.*
103. Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I, Falzoi M, Dessi C, Curzu MM, Chelucci G, Pani L, Pinna GA. *Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J Med Chem. 2006 Dec 14;49(25):7502-12. PubMed PMID: 17149879.*

104. Murineddu G, Ruiu S, Loriga G, Manca I, Lazzari P, Reali R, Pani L, Toma L, Pinna GA. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. *J Med Chem.* 2005 Nov 17;48(23):7351-62. PubMed PMID: 16279795.
105. Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S. Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. *Eur J Pharmacol.* 2005 Nov 21;525(1-3):150-3. Epub 2005 Nov 3. PubMed PMID:16271359.
106. Saba L, Porcella A, Sanna A, Congeddu E, Marziliano N, Mongeau R, Grayson D, Pani L. Five mutations in the GABA A alpha6 gene 5' flanking region are associated with a reduced basal and ethanol-induced alpha6 upregulation in mutated Sardinian alcohol non-preferring rats. *Brain Res Mol Brain Res.* 2005 Jun 13;137(1-2):252-7. Epub 2005 Apr 18. PubMed PMID: 15950783.
107. Caboi F, Lazzari P, Pani L, Monduzzi M. Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. *Chem Phys Lipids.* 2005 Jun;135(2):147-56. Epub 2005 Mar 19. PubMed PMID: 15921975.
108. Casu MA, Pisu C, Sanna A, Tambaro S, Spada GP, Mongeau R, Pani L. Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study. *Brain Res.* 2005 Jun 28;1048(1-2):41-7. PubMed PMID:15913574.
109. Murineddu G, Ruiu S, Mussinu JM, Loriga G, Grella GE, Carai MA, Lazzari P, Pani L, Pinna GA. Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. *Bioorg Med Chem.* 2005 May 2;13(9):3309-20. PubMed PMID: 15809166.
110. Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. *Eur J Pharmacol.* 2004 Nov 3;504(1-2):61-4. PubMed PMID: 15507222.
111. Tambaro S, Ruiu S, Dessi C, Mongeau R, Marchese G, Pani L. Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays. *J Pharmacol Exp Ther.* 2005 Feb;312(2):710-7. Epub 2004 Oct 6. PubMed PMID: 15470085.
112. Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, Conley R, Scully P, Chue PS, Lachaux B. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. *Psychiatr Serv.* 2004 Sep;55(9):997-1005. Review. PubMed PMID: 15345759.
113. Racagni G, Canonico PL, Ravizza L, Pani L, Amore M. Consensus on the use of substituted benzamides in psychiatric patients. *Neuropsychobiology.* 2004;50(2):134-43. Review. PubMed PMID: 15292667.
114. Casti P, Marchese G, Casu G, Ruiu S, Pani L. Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. *Neuropharmacology.* 2004 Jul;47(1):128-35. PubMed PMID:15165840.

115. Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, Pani L, Ruiu S, Gessa GL. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. *Bioorg Med Chem.* 2004 Apr 15;12(8):1921-33. PubMed PMID: 15051060.
116. Sanna A, Congeddu E, Saba L, Porcella A, Marchese G, Ruiu S, Casti P, Saba P, Pani L. The cerebellar GABAA alpha6 subunit is differentially modulated by chronic ethanol exposure in normal (R100R) and mutated (Q100Q) sNP rats. *Brain Res.* 2004 Feb 20;998(2):148-54. PubMed PMID: 14751585.
117. Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E, Tambaro S, Pani L. Haloperidol versus risperidone on rat "early onset" vacuous chewing. *Behav Brain Res.* 2004 Feb 4;149(1):9-16. PubMed PMID: 14739005.
118. Marchese G, Bartholini F, Ruiu S, Casti P, Casu GL, Pani L. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. *Eur J Pharmacol.* 2004 Jan 1;483(1):65-9. PubMed PMID: 14709327.
119. Casu MA, Pisu C, Lobina C, Pani L. Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring rats. *Psychopharmacology (Berl).* 2004 Mar;172(3):341-51. Epub 2003 Nov 21. PubMed PMID: 14634717.
120. Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G, Pani L. Haloperidol, but not clozapine produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. *Br J Pharmacol.* 2003 Oct;140(3):520-6. Epub 2003 Aug 26. PubMed PMID: 12970091; PubMed Central PMCID: PMC1574061.
121. Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. *J Pharmacol Exp Ther.* 2003 Jul;306(1):363-70. Epub 2003 Mar 27. PubMed PMID: 12663689.
122. Sanna A, Congeddu E, Porcella A, Saba L, Pistis M, Peis M, Marchese G, Ruiu S, Lobina C, Grayson DR, Gessa GL, Pani L. Characterization of wild-type (R100R) and mutated (Q100Q) GABAA alpha 6 subunit in Sardinian alcohol non-preferring rats (sNP). *Brain Res.* 2003 Mar 28;967(1-2):98-105. PubMed PMID: 12650970.
123. Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL. Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. *Psychopharmacology (Berl).* 2003 Apr;167(1):79-84. Epub 2003 Mar 11. PubMed PMID: 12632247.
124. Congeddu E, Saba L, Porcella A, Sanna A, Marchese G, Lobina C, Gessa GL, Pani L. Molecular characterization of new polymorphisms at the beta2, alpha1, gamma2 GABA(A) receptor subunit genes associated to a rat nonpreferring ethanol phenotype. *Brain Res Mol Brain Res.* 2003 Feb 20;110(2):289-97. PubMed PMID:12591165.



125. Ruiu S, Marchese G, Saba PL, Satta R, Gessa G, Vaccari A, Pani L. *In vitro* evidence for the presence of [<sup>3</sup>H]-haloperidol uptake in rat brain. *Br J Pharmacol*. 2003 Jan;138(1):188-92. PubMed PMID: 12522089; PubMed Central PMCID: PMC1573635.
126. Koukopoulos A, Sani G, Koukopoulos AE, Minnai GP, Girardi P, Pani L, Albert MJ, Reginaldi D. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. *J Affect Disord*. 2003 Jan;73(1-2):75-85. PubMed PMID: 12507740.
127. Casu MA, Porcella A, Ruiu S, Saba P, Marchese G, Carai MA, Reali R, Gessa GL, Pani L. Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. *Eur J Pharmacol*. 2003 Jan 10;459(1):97-105. PubMed PMID: 12505538.
128. Pani L. Clinical implications of dopamine research in schizophrenia. *Curr Med Res Opin*. 2002;18 Suppl 3:s3-7. Review. PubMed PMID: 12418605.
129. Casu MA, Dinucci D, Colombo G, Gessa GL, Pani L. Reduced DAT- and DBH-immunostaining in the limbic system of Sardinian alcohol-preferring rats. *Brain Res*. 2002 Sep 6;948(1-2):192-202. PubMed PMID: 12383975.
130. Pani L, Horal M, Loeken MR. Polymorphic susceptibility to the molecular causes of neural tube defects during diabetic embryopathy. *Diabetes*. 2002 Sep;51(9):2871-4. PubMed PMID: 12196484.
131. Marchese G, Bartholini F, Ruiu S, Casti P, Saba P, Gessa G, Pani L. Effect of the amisulpride isomers on rat catalepsy. *Eur J Pharmacol*. 2002 May 24;444(1-2):69-74. PubMed PMID: 12191584.
132. Porcella A, Marchese G, Casu MA, Rocchitta A, Lai ML, Gessa GL, Pani L. Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. *Eur J Endocrinol*. 2002 Aug;147(2):255-61. Erratum in: *Eur J Endocrinol* 2002 Sep;147(3):434. PubMed PMID: 12153749.
133. Marchese G, Pani L. The role of limbic and cortical regions in schizophrenia: focus on dopamine. *Eur Psychiatry*. 2002 Aug;17 Suppl 4:349s-354s. PubMed PMID: 23573604.
134. Marchese G, Ruiu S, Casti P, Saba P, Gessa GL, Pani L. Effect of the amisulpride isomers on rat prolactinemia. *Eur J Pharmacol*. 2002 Jul 19;448(2-3):263-6. PubMed PMID: 12144950.
135. Marchese G, Ruiu S, Casti P, Bartholini F, Saba P, Gessa GL, Pani L. Carboxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. *Eur J Pharmacol*. 2002 Jun 28;447(1):109-14. PubMed PMID: 12106810.
136. Marchese G, Casu MA, Bartholini F, Ruiu S, Saba P, Gessa GL, Pani L. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. *Eur J Neurosci*. 2002 Apr;15(7):1187-96. PubMed PMID: 11982629.

137. Pani L, Gessa GL. *The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia.* *Mol Psychiatry.* 2002;7(3):247-53. Review. PubMed PMID: 11920152.
138. Pani L, Horal M, Loeken MR. *Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis.* *Genes Dev.* 2002 Mar 15;16(6):676-80. PubMed PMID: 11914272; PubMed Central PMCID: PMC155364.
139. Casu MA, Colombo G, Gessa GL, Pani L. *Reduced TH-immunoreactive fibers in the limbic system of Sardinian alcohol-preferring rats.* *Brain Res.* 2002 Jan 11;924(2):242-51. PubMed PMID: 11750910.
140. Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L. *(-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors.* *Eur J Pharmacol.* 2001 Dec 7;432(2-3):143-7. PubMed PMID: 11740949.
141. Devoto P, Flore G, Pani L, Gessa GL. *Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex.* *Mol Psychiatry.* 2001 Nov;6(6):657-64. PubMed PMID: 11673793.
142. Devoto P, Flore G, Ibba A, Fratta W, Pani L. *Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus accumbens dopamine release as studied by brain microdialysis.* *Toxicol Lett.* 2001 May 19;121(3):199-206. PubMed PMID: 11369474.
143. Saba L, Porcella A, Congeddu E, Colombo G, Peis M, Pistis M, Gessa GL, Pani L. *The R100Q mutation of the GABA(A) alpha(6) receptor subunit may contribute to voluntary aversion to ethanol in the sNP rat line.* *Brain Res Mol Brain Res.* 2001 Mar 5;87(2):263-70. PubMed PMID: 11245930.
144. Porcella A, Maxia C, Gessa GL, Pani L. *The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies.* *Eur J Neurosci.* 2001 Jan;13(2):409-12. PubMed PMID: 11168547.
145. Ruiu S, Marchese G, Saba PL, Gessa GL, Pani L. *The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex.* *Mol Psychiatry.* 2000 Nov;5(6):673-7. PubMed PMID: 11126398.
146. Pani L. *Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries?* *Mol Psychiatry.* 2000 Sep;5(5):467-75. Review. PubMed PMID: 11032379.
147. Porcella A, Maxia C, Gessa GL, Pani L. *The human eye expresses high levels of CBI cannabinoid receptor mRNA and protein.* *Eur J Neurosci.* 2000 Mar;12(3):1123-7. PubMed PMID: 10762343.
148. Pani L, Porcella A, Gessa GL. *The role of stress in the pathophysiology of the dopaminergic system.* *Mol Psychiatry.* 2000 Jan;5(1):14-21. Review. PubMed PMID: 10673764.

149. Porcella A, Gessa GL, Pani L. Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. *Eur J Neurosci.* 1998 May;10(5):1743-51. PubMed PMID: 9751146.
150. Porcella A, Casellas P, Gessa GL, Pani L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marijuana. *Brain Res Mol Brain Res.* 1998 Jul 15;58(1-2):240-5. PubMed PMID: 9685662.
151. Murru S, Pani L, Poddie D, Gessa G, Cao A, Pirastu M. Rat tyrosine hydroxylase gene polymorphisms. *Brain Res Mol Brain Res.* 1997 May;45(2):345-8. PubMed PMID: 9149112.
152. Collu M, Poggiu AS, Pani L, Serra G. Fluoxetine-induced conditioned place preference: a preliminary study. *Synapse.* 1997 Mar;25(3):309-11. PubMed PMID: 9068130.
153. Pani L, Gessa GL. Evolution of the dopaminergic system and its relationships with the psychopathology of pleasure. *Int J Clin Pharmacol Res.* 1997;17(2-3):55-8. Review. PubMed PMID: 9403354.
154. Akiskal HS, Bolis CL, Cazzullo C, Costa e Silva JA, Gentil V, Lecrubier Y, Licinio J, Linden M, Lopez-Ibor JJ, Ndiaye IP, Pani L, Prilipko L, Robertson MM, Robinson RG, Starkstein SE, Thomas P, Wang Y, Wong ML. Dysthymia in neurological disorders. *Mol Psychiatry.* 1996 Dec;1(6):478-91. Review. PubMed PMID: 9154250.
155. Galli R, Michelini S, Bartalena L, Massetani R, Pani L, Grasso L, Cassano GB, Martino E, Purdy RH, Murri L. Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase. *Ital J Neurol Sci.* 1996 Aug;17(4):277-81. PubMed PMID: 8915758.
156. Colangelo AM, Pani L, Mocchetti I. Correlation between increased AP-1/NGF binding activity and induction of nerve growth factor transcription by multiple signal transduction pathways in C6-2B glioma cells. *Brain Res Mol Brain Res.* 1996 Jan;35(1-2):1-10. PubMed PMID: 8717334.
157. Koukopoulos A, Pani L, Serra G, Minnai G, Reginaldi D. [Anxious-excited depression: a mixed affective syndrome]. *Encephale.* 1995 Dec;21 Spec No 6:33-6. Review. French. PubMed PMID: 8582315.
158. Samadani U, Porcella A, Pani L, Johnson PF, Burch JB, Pine R, Costa RH. Cytokine regulation of the liver transcription factor hepatocyte nuclear factor-3 beta is mediated by the C/EBP family and interferon regulatory factor 1. *Cell Growth Differ.* 1995 Jul;6(7):879-90. PubMed PMID: 7547510.
159. Fadda P, Pani L, Porcella A, Fratta W. Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. *Neurosci Lett.* 1995 Jun 9;192(2):121-3. PubMed PMID: 7675318.

160. Gessa GL, Pani L, Fadda P, Fratta W. Sleep deprivation in the rat: an animal model of mania. *Eur Neuropsychopharmacol.* 1995;5 Suppl:89-93. PubMed PMID:8775765.
161. Gessa GL, Pani L, Serra G, Fratta W. Animal models of mania. *Adv Biochem Psychopharmacol.* 1995;49:43-66. Review. PubMed PMID: 7653334.
162. Koukopoulos A, Reginaldi D, Minnai G, Serra G, Pani L, Johnson FN. The long term prophylaxis of affective disorders. *Adv Biochem Psychopharmacol.* 1995;49:127-47. PubMed PMID: 7653332.
163. Costa E, Cheney DL, Grayson DR, Korneyev A, Longone P, Pani L, Romeo E, Zivkovich E, Guidotti A. Pharmacology of neurosteroid biosynthesis. Role of the mitochondrial DBI receptor (MDR) complex. *Ann N Y Acad Sci.* 1994 Nov 30;746:223-42. Review. PubMed PMID: 7825880.
164. D'Aquila PS, Collu M, Pani L, Gessa GL, Serra G. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. *Eur J Pharmacol.* 1994 Sep 1;262(1-2):107-11. PubMed PMID:7813561.
165. Kolmer M, Alho H, Costa E, Pani L. Cloning and tissue-specific functional characterization of the promoter of the rat diazepam binding inhibitor, a peptide with multiple biological actions. *Proc Natl Acad Sci U S A.* 1993 Sep 15;90(18):8439-43. PubMed PMID: 7690962; PubMed Central PMCID: PMC47372.
166. Clevidence DE, Overdier DG, Tao W, Qian X, Pani L, Lai E, Costa RH. Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family. *Proc Natl Acad Sci U S A.* 1993 May 1;90(9):3948-52. PubMed PMID: 7683413; PubMed Central PMCID: PMC46423.
167. Cavallaro S, Pani L, Guidotti A, Costa E. ACTH-induced mitochondrial DBI receptor (MDR) and diazepam binding inhibitor (DBI) expression in adrenals of hypophysectomized rats is not cause-effect related to its immediate steroidogenic action. *Life Sci.* 1993;53(14):1137-47. PubMed PMID: 8396705.
168. Pani L, Overdier DG, Porcella A, Qian X, Lai E, Costa RH. Hepatocyte nuclear factor 3 beta contains two transcriptional activation domains, one of which is novel and conserved with the *Drosophila* fork head protein. *Mol Cell Biol.* 1992 Sep;12(9):3723-32. PubMed PMID: 1324404; PubMed Central PMCID: PMC360231.
169. Pani L, Quian XB, Clevidence D, Costa RH. The restricted promoter activity of the liver transcription factor hepatocyte nuclear factor 3 beta involves a cell-specific factor and positive autoactivation. *Mol Cell Biol.* 1992 Feb;12(2):552-62. PubMed PMID: 1732730; PubMed Central PMCID: PMC364229.
170. Devoto P, Pani L, Kuzmin A, De Montis G. Inhibition of [3H]dopamine uptake by flunarizine. *Eur J Pharmacol.* 1991 Oct 2;203(1):67-9. PubMed PMID: 1797556.

171. Diana M, Pani L, Rossetti Z, Passino N, Gessa GL. Flunarizine attenuates cocaine-induced inhibition of A9 dopaminergic neurons. *Pharmacol Res.* 1991 Aug;24(2):197-203. PubMed PMID: 1661005.
172. Pani L, Kuzmin A, Martellotta MC, Gessa GL, Fratta W. The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine. *Brain Res Bull.* 1991 Mar;26(3):445-7. PubMed PMID: 1828708.
173. Pani L, Kuzmin A, Stefanini E, Gessa GL, Rossetti ZL. Flunarizine potentiates cocaine-induced dopamine release and motor stimulation in rats. *Eur J Pharmacol.* 1990 Nov 6;190(1-2):223-7. PubMed PMID: 2076754.
174. Pani L, Kuzmin A, Diana M, De Montis G, Gessa GL, Rossetti ZL. Calcium receptor antagonists modify cocaine effects in the central nervous system differently. *Eur J Pharmacol.* 1990 Nov 6;190(1-2):217-21. PubMed PMID: 2076753.
175. Carboni S, Melis F, Pani L, Hadjiconstantinou M, Rossetti ZL. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+). *Neurosci Lett.* 1990 Sep 4;117(1-2):129-33. PubMed PMID: 1981252.
176. Colombo G, Kuzmin A, Fadda F, Pani L, Gessa GL. Conditioned place preference induced by ethanol in a rat line selected for ethanol preference. *Pharmacol Res.* 1990 Sep-Oct;22 Suppl 3:48. PubMed PMID: 2097641.
177. Pani L, Gessa GL, Carboni S, Portas CM, Rossetti ZL. Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release? *Eur J Pharmacol.* 1990 May 3;180(1):85-90. PubMed PMID: 2163865.
178. Pani L, Carboni S, Kusmin A, Gessa GL, Rossetti ZL. Nimodipine inhibits cocaine-induced dopamine release and motor stimulation. *Eur J Pharmacol.* 1990 Feb 6;176(2):245-6. PubMed PMID: 2311670.
179. Rossetti ZL, Portas C, Pani L, Carboni S, Gessa GL. Stress increases noradrenaline release in the rat frontal cortex: prevention by diazepam. *Eur J Pharmacol.* 1990 Feb 6;176(2):229-31. PubMed PMID: 2311668.
180. Rossetti ZL, Pani L, Kuzmin A, Carboni S, Gessa GL. Dihydropyridine calcium antagonists prevent cocaine-, but not amphetamine-, induced dopamine release and motor activity in rats. *Acta Physiol Hung.* 1990;75 Suppl:249-50. PubMed PMID:2371880.
181. Rossetti ZL, Pani L, Portas C, Gessa G. Brain dialysis provides evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. *Eur J Pharmacol.* 1989 Apr 25;163(2-3):393-5. PubMed PMID: 2566508.
182. Rossetti ZL, Pani L, Gessa GL. Differential postmortem release of noradrenaline and dopamine from rat brain. *Psychopharmacology (Berl).* 1989;98(4):562-3. PubMed PMID: 2505301.

183. Serra G, Collu M, D'Aquila P, Pani L, Gessa GL. Are D1 dopamine receptor agonists potential antidepressants? *Pharmacol Res Commun.* 1988 Dec;20(12):1121-2. PubMed PMID: 2905479.

18. *Books and Monographs Published:*

**Chapters in Books:**

1) Rossetti Z.L.; Pani L.; Portas C.; Carboni S.; Gessa G.L.

*Evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex in The Basal Ganglia III,*  
Bernardi et al. Eds., 1990

2) Tondo L; Pani PP; Pani L; Carcassi L; Manconi PE; Rudas N.

*T-Lymphocyte in depression in: The modes of depression: from psychobiology to psychodynamics.* Ravizza, Genazzani,  
Torta and Eva eds. Cortina. Torino, 1990

3) Costa E., Cheney D.L., Grayson D.R., Korneyev A., Longone P., Pani L., Romeo E., Zivkovich E., Guidotti A.

*Pharmacology of Neurosteroids Biosynthesis: Role of the Mitochondrial DBI receptor (MDR) complex. In Brain Corticosteroid Receptors: Studies on the Mechanism, Function, and Neurotoxicity of Corticosteroid Action.*  
Vol. 746 of *The Annals of the New York Academy of Sciences*, 1994, 223-242

4) Serra G., Pani L., Collu M, Gessa G.L.

*Ruolo delle Monoamine nella patogenesi dei disturbi dell'umore. In La depressione nel bambino e nell'adolescente.*  
G. Lanzi et al. (eds) 1994, 179-192

5) Koukopoulos A., Reginaldi D., Minnai G., Serra G., Pani L., Johnson FN

*The Long Term Prophylaxis of Affective Disorders in Depression and Mania: from Neurobiology to Treatment,*  
Gessa GL, Fratta W., Pani L and Serra G. (eds), Raven Press, May 1995, 127-147

6) Gessa G.L., Pani L., Serra W., Fratta W

*Animal Models of Mania in Depression and Mania: from Neurobiology to Treatment,*  
Gessa G.L., Fratta W., Pani L and Serra G. (eds), Raven Press, May 1995, 43-67

7) Gessa G.L., Serra G., Pani L.

*Biochimica della Distimia: il ruolo della dopamina*  
*Nuova Rivista di Neurologia, Suppl Vol. 5, 10-18 (1995)*

8) Pani L., Gessa G.L.

*The role of dopamine in the biological basis of dysthymia in Dysthymia in neurological disorders,*

*Proceedings of the WHO Meeting, J. Licinio; L. Prilipko and C.L. Bolis (eds), WHO Geneva, Switzerland, 1997.*

9) Pani L., Porcella A. and Gessa G.L.

*Stress and the dopaminergic System in Stress and the nervous system, Proceedings of the WHO Meeting,*

*J. Licinio and C.L. Bolis (eds), WHO Athens, Greece, 1998.*

10) *Serra G., Pani L., Gessa G.L.*

*Clozapina Enciclopedia Medica Italiana, Agg. II, Tomo I, 1284-1288, 1998*

11) *Pani L., Porcella A. and Gessa G.L.*

*Dysthymia: Psychosocial Aspects. in Dysthymia in Public Health, Proceedings of the Joint WHO/AIREN Meeting,*

*J. Licinio and C.L. Bolis (eds), WHO Geneva, Switzerland, In press, 1999.*

12) *Pani L., Porcella A, Gessa G.L.*

*Hypothesis testing: dopaminergic system, environmental pressure and evolutionary mismatch, in Dopaminergic System:*

*Evolution from Biology to Clinical Aspects,*

*Bolis CL, Pani L and Licinio J. (eds) Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001*

13) *Gessa G.L., Pani L, Devoto P*

*Is dopamine in the prefrontal cortex released from noradrenergic neurons? in*

*Dopaminergic System: Evolution from Biology to Clinical Aspects, Bolis CL, Pani L and Licinio J. (eds)*

*Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001*

14) *Pani L, Biggio G*

*Effetti collaterali delle benzodiazepine in Benzodiazepine dalle molecole alla pratica clinica, Biggio G, (ed), Springer-Verlaag Italia, Milano 2001*

15) *Canali S, De Anna G, Pani L*

*Evolutionary Psychopharmacology mental disorders and ethical behaviour in:*

*Evolutionary ethics and contemporary Biology, Boniolo G, (ed) Cambridge University Press Cambridge, 2006*

16) *Pani L, Saba L*

*Farmacogenetica degli Antipsicotici in:*

*Trattato Italiano di Psichiatria, Cassano GB (ed), Masson-Elsevier, Milano 2008*

17) *Salloum IM, Pani L, Cooke T*

*Management of Comorbidity in Bipolar Disorder in:*

*Bipolar Disorder: Clinical and Neurobiological Foundations, Edited by Lakshmi N. Yatham and Mario Maj, John Wiley & Sons, 2010*

18) *Pani L,*

*La fine Anatomia di un Asperger o, anzi, due: Santiago Felipe Ramón y Cayal in:*

*Sei personaggi in cerca di Autismi (a cura di Paolo Cornaglia Ferraris)*

*Edizioni LSWR, 2018*

**b) Books:**

1) *Gian Luigi Gessa e Luca Pani*

*Il ruolo della dopamina nei disturbi depressivi Parte Prima: Neurobiologia della Distimia: il ruolo della dopamina.*

*Mediserve Milano, 1998 (I edizione)*

2) *Luca Pani e Gian Luigi Gessa*

*Il ruolo della dopamina nei disturbi depressivi Parte Seconda Distimia: diagnosi e trattamento.*

*Mediserve Milano, 1998 (I edizione)*

3) *Gian Luigi Gessa e Luca Pani*

*Il ruolo della dopamina nei disturbi depressivi. Volume Unico*

*Mediserve Milano, 1999 (II edizione)*

4) *Gerardo Medea e Luca Pani*

*I Disturbi depressivi in Medicina Generale. Diagnosi e Gestione*

*UTET Periodici Milano, 2000*

5) *Luca Pani*

*La Biochimica del Cervello*

*Masson, Milano 2001*

6) *Stefano Canali e Luca Pani*

*Emozioni e malattia. Dall'evoluzione biologica al tramonto del pensiero psicosomatico*

*Paravia Bruno Mondadori Editori, Milano 2003*

7) *Luca Pani*

*Distimia: dal temperamento alla malattia*

*Masson, Milano 2004*

8) *Luca Pani*

*La Rivoluzione di Paul Janssen*

*Cinquant'anni di Terapia della Schizofrenia: dall'aloiperidolo al paliperidone*

*Elsevier, Milano 2009*

9) *Luca Pani*

*Le Carte di Ephedra.*

*Kalb Editore, Cagliari, Italy 2006 (168 pp.)*

10) *Pani L., Martinez F.*

*Prove di Volo: Manuale di Psiconautica Elementare.*

*Edra, Milano, MILANO, October 2015*

11) *Pani L., Corbellini*

*Imperfezioni Umane*

*Rubbettino, Cosenza, October 2015*

12) *Pani L.*



*L'innovazione sostenibile*  
Edra, Milano, MILANO, January 2016

13) Pani L.  
*Sustainable Innovation*  
Edra, Milano, MILANO, June 2016

15) Pani L., (dipinti di Martinez F.)  
*Prove di Volo II: Manuale di Psiconautica Normale.*  
Edra, Milano, MILANO, October 2016

16) Pani L.,  
*Lo strano caso Avastin-Lucentis. Perché tutti vogliono delle Agenzie Regolatorie indipendenti che però quasi nessuno può permettersi?*  
Edra, Milano, MILANO, July 2017

17) Pani L.,  
*The strange case of Avastin-Lucentis. Why everybody wants independent Regulatory Agencies that almost nobody can handle?*  
Edra, Milano, MILANO, September 2017

18) Pani L., Corbellini G.  
*Prescrivere Valore. Storia e Scienza dei Farmaci che ci fanno vivere piu' a lungo e meglio.*  
Edra, Milano, MILANO, September 2017

19) Pani L., (dipinti di Mulas PG.)  
*Buddha non è un bar: Psiconautica Nuda*  
Edra, Milano, MILANO, October 2017

20) Pani L.  
*Resilienza Farmaceutica*  
Edra, Milano, MILANO, December 2017

21) Pani L.  
*Pharmaceutical Resilience*  
Edra, Milano, MILANO, March 2018

22) Pani (dipinti di Mulas PG.)  
*E Adesso Spogliati. Tecniche di spogliarello mentale. I pensieri da buttare e quelli da tenere*  
Edra, Milano, MILANO, November 2019

23) Mantua V., Pani L.  
*Guida all'Uso dei Farmaci in Psichiatria*  
Edra Milano, MILANO, December 2019

24) Pani L., Capitano ME  
*Effetto Quarentena: Chi siamo e Cosa saremo Nella Stagione del Covid-19*  
Edra Milano, MILANO, May 2020

25) Cammarata S., Pani L.  
*Elementi di Scienze Regolatorie del Farmaco,*  
*Edra Milano, April 2022*

19. *Juried or Refereed Journal Articles or Exhibitions: -*

20. *Other Works, Publications and Abstracts:*

*Over 150 articles on the most prominent Italian Newspaper and Specialty Magazines requested by the Newspaper director on issues related to Mental Disorders, Evolutionary Mismatch, Digital Medicine and Health or Academic Policies*

*Starting with 1994, invited to give presentation in more than 1200 Conferences, Seminars, Expert Opinion, Round Tables etc. I have been a Member of Educational / Editorial Strategic Boards: not product specific until 2016 and sometime product specific afterwards and open to delegates primarily health care professionals and organized through a provider of medical education to pharmaceutical companies*

*I have been a Speaker in Medical Education Events: such events were not all product specific, open to all delegates (healthcare professionals), without restriction, and focused on psychopharmacology (animal models, relationship between PK profiles and clinical impact). I was involved as a paid speaker in some of these events, and in most cases the participation was together with other experts in the field. A list of the most recent can be provided upon request*

21. *Other Works Accepted for Publication: -*

## **V. Professional**

22. *Funded Research Awarded: IMI2 - Call 23 Call ID: H2020-JTI-IMI2-2020-23-two-stage Action Type: RIA – Research and Innovation Actions [Topic 1: Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework](#). Luca Pani European Coordinator (6.6 M Euro total budget) 2022-2025*

23. *Editorial Responsibilities:*

*2017-present Chief Editor of [PharmAdvances](#) the Journal of Italian Society for Pharmacology  
2017-present Chief Scientific Officer of Edra Publishing Company (<http://www.edraspa.com/>) which publishes more than 50% of all the medical texts in Italy and has a catalog of hundreds of scientific titles which I supervise and/or counsel about.*

*1993-2003 I have founded, launched and co-directed with PP Pani and GL Gessa, The Italian Journal of the Addictions ([www.medicinatossicodipendenze.it](http://www.medicinatossicodipendenze.it)) and I have selected, judged and edited the articles of the Journal over a decade.*

24. *Professional and Honorary Organizations:*

*2022- President Elect, International Society for Clinical Trials Managements, USA*

2021- Fellow Royal Society of Medicine (London)  
2018-Present Member Italian Society of Pharmacology  
2015-Present Member and Executive Committee Member (since 2018) of ISCTM | The International Society for CNS Clinical Trials and Methodology  
2016-Present Conference Steering Committee Member | American Society of Clinical Psychopharmacology (ASCP)  
2017-Present ECNP New Frontiers Meeting programme Committee Member  
2009-2012 Scientific Advisor of the Psychotic Disorders and Antipsychotic Panel of the European College of Neuropsychopharmacology (ECNP).  
1990-present Italian Society of Pharmacology;  
1990-2010 Italian Society of Psychopathology;  
1995-2010 Italian Society of Psychiatry.

25. *Honors and Awards:*

2021- Gelfand Lecture US National Invitation Phi Delta Epsilon Medical Fraternity  
2019- IBDO Award – Galileo Galilei Medal, IBDO Foundation, Rome, Italy  
2014- Eurordis Prize for Innovation, Brussel, Belgium  
1994-1996-1998 Platano d'Oro: Italian National Medical Writing Prize, Finalist in all the first three editions of the prize, Cagliari, Italy  
1990-1991 Fidia Research Foundation International Fellowship in Neuroscience, Washington DC, USA

26. *Post-Doctoral Fellowships:*

1990-1992 Post Doctoral Fellow in Molecular Biology University of Illinois at Chicago, USA

27. *Other Professional Activities:*

I am one of the inventors (I do not have ownership) of two new U.S. and one E.C. Patents namely:  
US2010029622A1 on Microemulsion  
US2010028257A1 on Novel Omeperazines Opioids  
EP2223681A1 on Composition of spores of non pathogenic bacteria

**VI. Teaching**

2018- present Pharmacology and Clinical Pharmacology – Full Course for Medical School Students and Residents – University of Modena and Reggio Emilia – Italy  
2017- present Clinical Psychiatry and Psychopharmacology – I and III year Medical Students and MD, MPH Curriculum – PGY 1-4 Residents in Psychiatry – University of Miami – School of Medicine  
1994-2017 I have taught for over two decades both specialty psychopharmacology and clinical psychiatry to the medical resident program and medical school students both in Italy and USA. Since 1994, I have held as supervisor, organizer, chairperson and speaker for hundreds of CME courses and conferences worldwide.

28. *Teaching Awards Received:*

2021- Gelfand Prize US National Phi Delta Epsilon Medical Fraternity

29. *Teaching Specialization:*

Clinical Psychiatry - Psychopharmacology – Digital Medicine

30. *Thesis and Dissertation Advising/Post-doctoral Student Supervision:*

*I have been mentor and/or advisor for several dissertation and post-doctoral thesis in the Medicine or Pharmacy Faculty in Italy.*

## **VII. Service**

31. *University Committee and Administrative Responsibilities:*

*From 2010 I joined the top worldwide regulatory community in the field of Medicines at the European Medicines Agency (EMA) in London. I served from 2011 to 2016 as Director General of the Italian Medicine Agency (AIFA) – a ranking somewhat equivalent to a Deputy Minister of Health - responsible for the country's approval and reimbursement of human therapeutically active products for an equivalent of almost 30 billion Euro per year. Under my guidance AIFA implemented the first Conflict of Interest regulation and won (for four years in a row) the Italian Government prize for the most transparent public administration in Italy. I have supervised and managed a work force of over 400 specialists and succeeded in obtaining Italian Parliament's approval to increase AIFA's staff to 630 personnel. As Chair of important EMA's Committees and Working Parties I have coordinated the execution of the European pharmacovigilance directive and the multiannual working plan in the telematics strategy of the European Medicines Agency for the benefit of the entire national competent authorities' network.*

*In the previous 15 years I have supervised and followed to successful completion several project and research grants both at regional, national and international level. I have worked on all major molecular biology techniques with respect to gene expression; General and Molecular Pharmacology; Brain Microdialysis and Animal models; and I possess advanced Clinical Skills in Psychiatry.*

*I have also managed large organization with groups up to 400 individuals with multiple competences and have been personally interacting both at the national and international level with Government, Patients Organization, Health Care Providers Professionals, Charities, Payers and Industry.*

32. *Active Grants:*

*European Commission IMI-2 TOPIC ID: IMI2-2020-23-01 Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework*

**COORDINATOR:** Luca Pani University of Modena and Reggio Emilia, Modena, ITALY.

**TITLE:** FACILITATE (FrAmework for ClinIcal triaL partIcipants' daTa reutilizAtion for a fully Transparent and Ethical ecosystem)

**DURATION:** 4 years, Awarded May 31<sup>st</sup>, 2021 – Start Date from Jan 1<sup>st</sup>, 2022 to end date Dec., 31<sup>st</sup> 2025

**PARTNERS:** 27, of which 20 UE (Italia, Austria, Belgium, Finland, France, Germany, Netherlands, Cech Republic, Poland, Romania, Spain, Sweden) e 7 extra-UE (Serbia, Switzerland, USA, UK)

**Public/private:** 18 partners, of which 4 Universities/Research Centers, 6 Hospital Centers, 3 citizens/patients representatives, 5 for profit companies

**Industry:** 9 EFPIA members, of which 8 Pharma, 1 Service/Technology provider

**BUDGET:** € 3.260.000 EU contribution + € 3.363.904 In-kind = € 6.623.904

**BOARDS:** 3 Decision Experts Committees: Patient Associations, Ethical committees, Data protection authorities, National Medicine/Drug Regulators, Healthcare professionals, Researchers, Geneticists